Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 493

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 493
---
We
are not currently a party to any current or pending material legal proceedings. From time to time, however, the Company may be involved
in various disputes and litigation matters that arise in the ordinary course of business. The Company may face claims brought by third
parties, or, from time to time, the Company may make claims or take legal actions to assert our rights. Regardless of the outcome, any
such claims or legal proceedings could adversely impact our business, reputation, operating results, and financial condition because
of defense and settlement costs, diversion of resources, and other factors. Results of actual and potential litigation are inherently
uncertain, and there can be no assurances that favorable outcomes will be obtained.

Item
4. Mine Safety Disclosures.

Not
applicable.

 53 

PART
II

Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market
Information

Our
Common Stock, par value $0.007 per share (the “Common Stock”) trades under the symbol “BIAF.” Our tradeable warrants,
each to purchase one share of Common Stock (collectively, the “Tradeable Warrants”), trade under the symbol “BIAFW.”
Our Common Stock and Tradeable Warrants trade on The Nasdaq Capital Market.

Holders
of Record

As
of March 17, 2025, there were approximately 92 holders of record of shares of our Common Stock. This number does not reflect
the beneficial holders of our Common Stock who hold shares in street name through brokerage accounts or other nominees.

Dividends

We
have never declared or paid any cash dividends on our capital stock. We intend to retain all available funds and future earnings, if
any, to fund the development and expansion of our business, and we do not anticipate declaring or paying any cash dividends in the foreseeable
future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our Board of
Directors and will depend on then-existing conditions, including our financial condition, results of operations, contractual restrictions,
capital requirements, business prospects, and other factors our Board of Directors may deem relevant.

Unregistered
Sales of Equity Securities

We
did not sell any equity securities during the quarter ended December 31, 2024, in transactions that were not registered under the Securities
Act other than as previously disclosed in our filings with the SEC.

Securities
Authorized for Issu